Lack of association between NOS3 Glu298Asp and breast cancer risk: a case-control study.
Nitric oxide (NO) plays a central role in the physiololgy and pathology of diverse tissues. Different studies provide data suggesting that the endothelial cell nitric oxide synthase (NOS3) expression in peritumoral microvessels might be a prognostic indicator in breast cancer patients. However, the putative contribution of common NOS3 germline variants to breast cancer risk remained unknown. A recent work comprising 269 breast cancer patients and 244 controls suggested that NOS3 Glu298Asp polymorphism is associated to breast cancer risk (OR=1.9). We performed an independent analysis of these results in 440 unrelated patients and 321 controls from Spanish population. Although our study was 90% powered to detect ORs >/=1.55, did not find any significant difference in the Glu298Asp allele distribution between cases and controls (P > 0.42). These putative reasons for this result are discussed.
Royo
Jose Luis
JL
Moreno-Nogueira
José Andrés
JA
Galán
Jose Jorge
JJ
González-Martín
Antonio
A
Ruiz
Agustin
A
González-Mancha
Rosario
R
Real
Luis Miguel
LM
D001224:Aspartic Acid; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D018698:Glutamic Acid; D006801:Humans; D052250:Nitric Oxide Synthase Type III / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D012307:Risk Factors; D013030:Spain
D001224:Aspartic Acid; D018698:Glutamic Acid; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III